Rivia’s AI-driven data platform addresses the critical inefficiencies in the current clinical trial process, providing a real-time, integrated view of trial data to accelerate the path to market for new therapies. The company has secured a €3M Seed funding round led by Speedinvest.
Founded by seasoned biopharma experts familiar with the industry's pain points, Rivia focuses on creating user-friendly software tailored to the needs of biotech firms. Rivia addresses a significant inefficiency in the industry: current data collection advancements are not matched by system integration capabilities or user-friendly web applications. Data is fragmented and visualization tools are outdated. Rivia empowers biotechs to analyze trial data more effectively, facilitating quicker and more efficient pathways to market for their therapies. Rivia's impact is already noticeable with clients across Europe and the US, including Abcentra. Rivia was founded in 2022 and currently has a staff of seven.
Rivia has secured a €3M Seed funding round led by Speedinvest alongside Amino Collective and Nina Capital. The funds will be used to hire new teams across engineering and client services, and will also advance product development to fully harness the potential of integrated trial data and strengthen its position as the unified data platform for biopharma clinical trials.
Erik Scalfaro, CEO and co-founder of Rivia said: "Our technology transcends data integration and changes how biotechs evaluate their therapies throughout their development lifecycle. Our founding expertise lies in consolidating information from clinical trial service providers and offering self-service analytics for medical and clinical operations. This year, we’re introducing AI-powered analytics and AI-enabled workflows to enhance data interactions."
“Rivia’s AI backed technology represents a huge innovation opportunity to equip biotech companies with the advanced tools needed to analyse their trial data and make informed decisions”, commented Andrea Zitna, Partner at Speedinvest.
“In the last four years, we at Nina Capital have evaluated over 450 early-stage startups selling software to biotechs and pharmaceutical companies with a value proposition focused on improving preclinical R&D or clinical trial operations. We have also seen over 200 focused on health data portability, serving customers including but beyond the Life Sciences industry. Rivia stands out for its unique approach to centralizing and visualizing multiple sources of clinical trial data in real-time, requiring minimal integration efforts and enabling proactive patient monitoring , explained Marta G. Zanchi, Founder & Managing Partner at Nina Capital.
(Press release / SK)
Photo: Rivia founders Tiago Kieliger CTO (left), Erik Scalfaro CEO
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines